Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians

Figure 2. The meta-analysis was done by using a random-effects model because of between-study heterogeneity ( = 0.026). 4S
= Scandinavian Simvastatin Survival Study; CARE = Cholesterol and Recurrent Events trial; HPS-2 = Heart Protection Study (secondary
prevention arm); LIPID = Long-term Intervention with Pravastatin in Ischemic Disease trial; LIPS = Lescol Intervention Prevention
Study; Post-CABG = Post–Coronary Artery Bypass Graft trial; PROSPER-2 = Prospective Study of Pravastatin in the Elderly at
Risk (secondary prevention arm); VA-HIT = Veterans Administration High-Density Lipoprotein Cholesterol Intervention Trial.
Meta-analysis of the absolute risk reduction of lipid-lowering as secondary prevention in patients with diabetes.P
-
Ann Intern Med
April 20, 2004
vol. 140
no. 8
650-658